Fri, Mar 6, 2015, 8:03 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • mcguireryan38 mcguireryan38 Sep 11, 2013 9:10 AM Flag

    morgan stanley

    should be interesting to see what info is released...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Only thing I could understand was strong potential but more tests are needed before commercialization. Also, would Europe be tougher? I thought it would be easier. Clarification anyone.

      Sentiment: Hold

      • 1 Reply to wampum1m
      • For a company with 1 marketed product, /intermune has an awful lot of moving parts. And a bunch of them were touched on. Start with Jakafi (the name means Ruxolitinib used on-label, that is for myelofibrosis, and in the US). Jakavi is the same in Europe (roll-outs in Europe happen slowly because of national and even finer-grained regulatory differences). Then there's Ruxo off-label for polycythemia vera (off-label but soon to be brought on) and Ruxo off-label for solid tumors (probably already happening, but far from coming on label). Physicians may use a marketed drug pretty much as they please.

        Not-yet-marketed are Baricitinib, "The emerging pipeline" (mostly JAK inhibitors with mixes of specificities different from marketed ones) and the 2 anti-cancer candidates (IDO and cMet inhibitors).n hour is bound to be confusing.

        Having all those stories touched on in half a

    • Nice way of handling it. No introduction, jump to Q&A. Nice to see the neutropenia/margination issue reopened, because that had the potential to be a killer and it seems to be coming down all pro-Jakafi in practice. All the hinting around the magic subset has me thinking that it might be something non-obvious to outsiders. Also, much hinting about early stage testing in a lot of possible solid tumor indications. There was some hinting about a possible instance of what I call the staging paradox (but is more often called The Will Rogers Phenomenon) in the PaCa data (this usually reduces the impact of a result, but in this instance it was a suggestion that even though casual analysis suggested that only the magic subset was helped by Ruxo, the detailed analysis is at least leaving the question open). The message that emerging-from-pipeline candidates are unencumbered was emphasized heavily. There was some braggadocio about the financial strength of Incyte (we could do anything independently....well except for a heart drug...) that frankly sounded delusional.

    • As I jumped the gun and said last week, this one ought to be fun. These conference presentations are usually G-rated peep shows.

    • Agreed....Looking forward to it. Wonder how Morgan Stanley's analyst will feel when/if more good news is released or garnered. That sell rating may change. :)

      Sentiment: Strong Buy

90.00-1.97(-2.14%)Mar 6 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.